JGC
AEGR

J. Goldman & Co’s Aegerion Pharmaceuticals AEGR Stock Holding History

J. Goldman & Co’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-87,500
Closed -$884K – 403
2015
Q4 		$884K Buy
+87,500
New +$1.05M 0.09% 183
2014
Q1 		– Sell
-73,700
Closed -$5.23M – 332
2013
Q4 		$5.23M Buy
+73,700
New +$5.64M 0.66% 33

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

J. Goldman & Co's AEGR Position: Q1 2016 in Review

J. Goldman & Co sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2016, closing a stake of 3,189 shares — an estimated $32K sold.

J. Goldman & Co first reported a position in AEGR in Q1 2015 and held it in 3 quarters. The position peaked at $3.72M in Q1 2015. 101 funds tracked by Wall St. Rank hold AEGR as of Q1 2016.

  • J. Goldman & Co reported no remaining Aegerion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • J. Goldman & Co sold 3,189 Aegerion Pharmaceuticals shares in Q1 2016, an estimated $32K.
  • J. Goldman & Co first reported a position in Aegerion Pharmaceuticals in Q1 2015 and held it in 3 quarters.
  • J. Goldman & Co's Aegerion Pharmaceuticals position peaked at $3.72M in Q1 2015.
  • 101 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2016.

Based on J. Goldman & Co's 13F filing for Q1 2016, filed 16 May 2016.